• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α-突触核蛋白和 tau 基因型与帕金森病进展的相互作用。

Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.

机构信息

Neuroscience Research Australia and The University of New South Wales, Sydney, Australia.

出版信息

J Parkinsons Dis. 2011;1(3):271-6. doi: 10.3233/JPD-2011-11027.

DOI:10.3233/JPD-2011-11027
PMID:23939307
Abstract

OBJECTIVE

To determine whether α-synuclein NACP-Rep1 and tau genotypes can predict the rate of progression of Parkinson's disease.

METHODS

123 Parkinson's disease cases were recruited for neurological examination and DNA donation. The rate of progression was assessed as the motor Unified Parkinson's disease Rating Score divided by symptom duration at the time of assessment and associations determined with α-synuclein NACP-Rep1 and tau genotypes.

RESULTS

There was a significant effect of genotype on the rate of progression of Parkinson's disease. In MAPT H2 haplotype carriers, some NACP-Rep1 genotypes, thought to be associated with increasing α-synuclein expression, were linked with a higher rate of progression. In NACP-Rep1 0/0 genotype carriers, patients without MAPT H2 haplotype had a higher rate of progression of Parkinson's disease. The relative risk to develop a more rapid disease progression in these genotypes reached 5.8.

CONCLUSION

Genetic factors not only influence the risk of Parkinson's disease, but also the progression of Parkinson's disease.

摘要

目的

确定α-突触核蛋白 NACP-Rep1 和 tau 基因型是否可以预测帕金森病的进展速度。

方法

招募了 123 例帕金森病患者进行神经学检查和 DNA 捐赠。进展速度评估为评估时运动统一帕金森病评定量表评分除以症状持续时间,并与α-突触核蛋白 NACP-Rep1 和 tau 基因型相关联。

结果

基因型对帕金森病的进展速度有显著影响。在 MAPT H2 单倍型携带者中,一些被认为与α-突触核蛋白表达增加相关的 NACP-Rep1 基因型与更高的进展速度相关。在 NACP-Rep1 0/0 基因型携带者中,没有 MAPT H2 单倍型的患者帕金森病的进展速度更快。这些基因型发生更快速疾病进展的相对风险达到 5.8。

结论

遗传因素不仅影响帕金森病的风险,还影响帕金森病的进展速度。

相似文献

1
Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.α-突触核蛋白和 tau 基因型与帕金森病进展的相互作用。
J Parkinsons Dis. 2011;1(3):271-6. doi: 10.3233/JPD-2011-11027.
2
Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.帕金森病中α-突触核蛋白与tau基因分型的相互作用。
Ann Neurol. 2005 Mar;57(3):439-43. doi: 10.1002/ana.20387.
3
Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease.SNCA基因的变异与运动进展相关,而MAPT基因的变异与帕金森病的严重程度相关。
Parkinsonism Relat Disord. 2016 Mar;24:89-94. doi: 10.1016/j.parkreldis.2015.12.018. Epub 2015 Dec 30.
4
SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians.α-突触核蛋白基因(SNCA)而非微管相关蛋白tau基因(MAPT)影响中国人和澳大利亚人帕金森病的发病年龄。
Biomed Res Int. 2015;2015:135674. doi: 10.1155/2015/135674. Epub 2015 Apr 15.
5
Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset.α-突触核蛋白Rep1多态性与帕金森病的关联:Rep1对发病年龄的影响。
Mov Disord. 2006 Apr;21(4):534-9. doi: 10.1002/mds.20752.
6
Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease.帕金森病中α-突触核蛋白(SNCA)与微管相关蛋白tau(MAPT)基因型之间缺乏相互作用。
Eur J Neurol. 2011 Mar;18(3):e32. doi: 10.1111/j.1468-1331.2010.03245.x. Epub 2010 Nov 4.
7
Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.澳大利亚的数据及荟萃分析支持将α-突触核蛋白(NACP-Rep1)作为帕金森病的一个风险因素。
Neurosci Lett. 2005 Feb 28;375(2):112-6. doi: 10.1016/j.neulet.2004.10.078. Epub 2004 Nov 23.
8
MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies.MAPT H1 单倍型与路易体痴呆中 α-突触核蛋白沉积增强相关。
Neurobiol Aging. 2013 Mar;34(3):936-42. doi: 10.1016/j.neurobiolaging.2012.06.015. Epub 2012 Jul 21.
9
Alpha-synuclein repeat variants and survival in Parkinson's disease.α-突触核蛋白重复变异与帕金森病的生存率
Mov Disord. 2014 Jul;29(8):1053-7. doi: 10.1002/mds.25841. Epub 2014 Feb 27.
10
Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.LRRK2 p.R1398H 对帕金森病风险的保护作用独立于 MAPT 和 SNCA 变异。
Neurobiol Aging. 2014 Jan;35(1):266.e5-14. doi: 10.1016/j.neurobiolaging.2013.07.013. Epub 2013 Aug 17.

引用本文的文献

1
Assessment tools for cognitive performance in Parkinson's disease and its genetic contributors.帕金森病认知功能及其遗传因素的评估工具。
Front Neurol. 2024 Jun 26;15:1413187. doi: 10.3389/fneur.2024.1413187. eCollection 2024.
2
Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches.帕金森病:从遗传学到分子功能障碍及靶向治疗方法
Genes Dis. 2022 Feb 5;10(3):786-798. doi: 10.1016/j.gendis.2021.12.015. eCollection 2023 May.
3
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn ("line 61") Mice.
一种用于测试帕金森病新疗法的小鼠模型:Thy1-aSyn(“line 61”)小鼠的最新研究进展。
Neurotherapeutics. 2023 Jan;20(1):97-116. doi: 10.1007/s13311-022-01338-0. Epub 2023 Jan 30.
4
A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease.帕金森病中常见SNCA变异与临床异质性之间关联的系统评价。
NPJ Parkinsons Dis. 2021 Jul 1;7(1):54. doi: 10.1038/s41531-021-00196-5.
5
Tau in the Pathophysiology of Parkinson's Disease.tau 在帕金森病的病理生理学中的作用。
J Mol Neurosci. 2021 Nov;71(11):2179-2191. doi: 10.1007/s12031-020-01776-5. Epub 2021 Jan 18.
6
Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinson's disease over five years follow-up.便秘和睡眠行为障碍与帕金森病男性患者五年随访期间的加工速度和注意力有关。
Sci Rep. 2020 Nov 4;10(1):19014. doi: 10.1038/s41598-020-75800-4.
7
Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.帕金森病认知和运动进展的全基因组关联研究。
Mov Disord. 2021 Feb;36(2):424-433. doi: 10.1002/mds.28342. Epub 2020 Oct 28.
8
SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians.α-突触核蛋白基因(SNCA)而非微管相关蛋白tau基因(MAPT)影响中国人和澳大利亚人帕金森病的发病年龄。
Biomed Res Int. 2015;2015:135674. doi: 10.1155/2015/135674. Epub 2015 Apr 15.
9
Mitochondrial dysfunction and oxidative stress in Parkinson's disease.帕金森病中的线粒体功能障碍和氧化应激。
Prog Neurobiol. 2013 Jul-Aug;106-107:17-32. doi: 10.1016/j.pneurobio.2013.04.004. Epub 2013 Apr 30.
10
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.一种帕金森病的进展型小鼠模型:Thy1-aSyn(“Line 61”)小鼠。
Neurotherapeutics. 2012 Apr;9(2):297-314. doi: 10.1007/s13311-012-0104-2.